# Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

> **NCT01818076** · PHASE3 · TERMINATED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 311 (actual)

## Conditions studied

- Skin Aging

## Interventions

- **DRUG:** Botulinum Toxin Type A

## Key facts

- **NCT ID:** NCT01818076
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-12
- **Target enrollment:** 311 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study (not due to safety reasons)
- **Last updated:** 2014-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818076, "Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01818076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*